TYRP1 and neoplasm: Kos et al. reported a recombinant chimeric analog of the murine mAb 2A2, which retained the binding properties of the parental murine antibody and its ability to inhibit CatB activity, mAb 2A2 significantly reduced extracellular matrix degradation and tumor cell invasion in vitro [93].